Extract
Desquamative interstitial pneumonia (DIP) was originally described by Liebow et al. [1] in 1965, and so named because of the observation of cells filling the alveolar spaces and the belief that this feature was due to desquamation of alveolar epithelial cells. It has since been recognised that the dominant histologic feature of DIP represents accumulation of intra-alveolar macrophages, and sometimes of giant cells [2]. Although the more accurate terminology of “alveolar macrophage pneumonia” has been proposed, the term DIP has persisted [3].
Abstract
In 2020, DIP is no longer idiopathic but remains orphan within the group of interstitial pneumonia. Disease course is not always benign. International collaboration is warranted to enable prospective studies. https://bit.ly/2YmR6B0
Footnotes
Provenance: Commissioned article, peer reviewed
Conflict of interest: V. Cottin reports personal fees and non-financial support from Actelion and from Roche/Promedior; grants, personal fees and non-financial support from Boehringer Ingelheim; and personal fees from Bayer/MSD, Novartis, Sanofi, Celgene, Galapagos, Galecto, Shionogi, AstraZeneca and Fibrogen, outside the submitted work.
- Received June 7, 2020.
- Accepted June 9, 2020.
- Copyright ©ERS 2020.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.